NCT05254782Recruiting
Using ctDNA to Detect Minimal Residual Disease After Lung Cancer Resection
From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection (ctDNALung-Detect)
Source: ClinicalTrials.gov · Last updated 9 Jun 2026
Brief summary (registry, in English)
ctDNALung-Detect is an investigator-initiated single arm, multi-institution study designed to assess the ctDNA detection rate and its association with Relapse Free Survival (RFS) in operable stage T1-T4 (T3,T4 multifocal) N0M0 non-small cell lung cancer (NSCLC) patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 360 (estimated)
- First submitted
- 14 Feb 2022
- Start date
- 6 Jul 2021
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Lung cancer
- NCT number
- NCT05254782
What you commit to
- Study type: Observational
- Planned participants: 360
- From 6 Jul 2021 to the primary completion date, 31 Mar 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radiation, surgery or chemotherapy for the current diagnosis of NSCLC is not permitted.
- Incomplete surgical resection. Participants who had pre-operative ctDNA samples taken but subsequently do not have a complete surgical resection would not qualify for post-operative ctDNA testing.
- Concurrent enrolment in a therapeutic study using drug or radiation therapy. Enrolment in observational, diagnostic or studies of novel surgical techniques will be allowed.
- Concurrent active malignancy or other invasive malignancy within previous 2 years. Non-invasive malignancies (i.e., cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured) are excluded from this definition.
Other
- Pregnancy.
Who the study is looking for
- Age ≥ 18 years;
- Ability to provide written informed consent;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- T1-T4 (T3,T4 multifocal) N0M0 NSCLC who are planned for complete surgical resection;
- Tumour size must be at least 1 cm (unidimensional) and have at least some solid component on imaging;
- Surgical tumour formalin-fixed, paraffin-embedded (FFPE) specimens for ctDNA studies are required.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. Joseph's Health Centre Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
| University Health Network Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
| Michael Garron Hospital Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
Related publications
- Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay.J Thorac Oncol · 2026 · PMID 41730473
This page is information, not medical advice. Discuss any trial with your doctor.